Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT06981507
Active, not recruiting Not applicable

Evaluation of the Effect of MARPE on Speech

NCT06981507 · tracked via the Priya Life Science Turkey tracker
Sponsor
Konya Necmettin Erbakan Üniversitesi
Phase
Not applicable
Started
2025-02-10
Last updated
2025-09-02

Condition(s) studied

Evaluation of Speech Characteristics Following MARPE Treatment in Patients With Maxillary Transverse Deficiency

Investigational drug(s) / intervention(s)

MARPE (Miniscrew-Assisted Rapid Palatal Expansion)

MARPE (Miniscrew-Assisted Rapid Palatal Expansion): MARPE (Miniscrew-Assisted Rapid Palatal Expansion) is an orthodontic expansion technique that uses a palatal expander anchored with miniscrews inserted into the palatal bone. The device applies lateral force to widen the maxilla skeletally in patients with transverse maxillary deficiency. In this study, all participants will receive MARPE treatment as part of their orthodontic management, and its potential effects on speech will be evaluated over time.

Study summary

This study investigates the effects of Miniscrew-Assisted Rapid Palatal Expansion (MARPE) on speech characteristics in adolescent and young adult patients.

While MARPE is a widely used orthodontic procedure for treating maxillary transverse deficiency, its potential impact on speech production has not been thoroughly evaluated. The aim of this study is to assess whether MARPE treatment causes any temporary or long-term changes in speech patterns using acoustic and perceptual analysis methods.

Eligibility

Sex
ALL
Min age
15 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with Class I malocclusion * Presence of maxillary transverse deficiency * Young adult patients aged 15 to 18 years * No history of systemic disease, cleft lip/palate, or speech disorders * No history of previous orthodontic treatment Exclusion Criteria: * Patients with any systemic disease * Patients who smoke * Patients with poor oral hygiene * Patients with cooperation difficulties * Patients with mental retardation or cognitive impairment

Primary outcome measure(s)

  • Speech Changes After MARPE Treatment — Baseline and 1 month after expansion

Trial sites (1)

FacilityCityRegionStatus
Necmettin Erbakan University, Faculty of Dentistry Konya Meram

More Konya Necmettin Erbakan Üniversitesi trials in Turkey

MARPE-Associated Changes in Sleep and Airway Recruiting
Looksmaxxing AI for Chin Deviation Detection Active, not recruiting
Effect of Serum Vitamin D on MARPE Treatment Response Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06981507 on ClinicalTrials.gov ↗ ← All trials in Turkey